Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lawsuits
Pharma
AZ-Summit, Novo-Hengrui, Merck—Fierce Pharma Asia
AstraZeneca invests in Summit, Novo bought a GLP-1/GIP drug from Hengrui, and Merck got a preclinical RAS(ON) inhibitor from China's SciBrunch.
Angus Liu
Oct 2, 2026 9:35am
PhRMA's Medicare price negotiation appeal sputters out
Aug 27, 2026 10:42am
Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads
Jul 21, 2026 9:18am
Sanofi sues Pfizer, Moderna over mRNA patents
Jul 15, 2026 3:32pm
SCOTUS ruling blunts state-level claims against Bayer's Roundup
Jun 25, 2026 1:52pm
Lilly accuses church-linked firms of rebate fraud scheme
May 21, 2026 3:37pm
